Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Brain Behav Immun. 2022 Sep 26;107:47–52. doi: 10.1016/j.bbi.2022.09.012

Fig 1. P2X7 antagonist inhibits METH-induced locomotor activation and CPP.

Fig 1.

(A) Locomotor time course: Mice pretreated with A438079 (0, 5, 10, or 50 mg/kg) were injected with METH (1 mg/kg) or saline 30 min later (at time 0). Locomotor activity presented as mean locomotor counts. N=8 mice/group. (B) Cumulative locomotor activity: Time-course data from (A) were quantified and presented as cumulative locomotor counts for the 90 min-interval following METH injection. **p < 0.01 versus drug-naïve mice (A438 (0 mg) + SAL) or +p < 0.05 versus mice treated with METH by itself (A438 (0 mg) + METH). N=8 mice/group. (C) CPP: Data are presented as a difference score (difference in time spent on METH-paired side between post-test and pre-test). N=7–8 mice/group. *p < 0.05 versus drug-naïve mice (A438 (0 mg) + SAL) or +p < 0.05 versus mice conditioned with METH alone (A438 (0 mg) + METH).